Role of oral colchicine in plaque type psoriasis. A randomized clinical trial comparing with oral methotrexate
DOI:
https://doi.org/10.66344/jpad.v20i3.408Abstract
Background Patients with moderate to severe psoriasis generally require phototherapy, photochemotherapy or systemic agents to control their disease adequately. The potential toxic effects of long term use of the classic antipsoriatics, prolonged continuous therapy, higher cost and low socio-economic conditions of patients obligate us to consider some cheaper older alternatives like colchicine.
Patients and methods A prospective, randomized controlled clinical trial was carried out on two groups of patient of psoriasis, group A (Case, n=30) was treated with 2.1 mg per day oral colchicine, in two divided doses and group B (Control, n= 30) was treated with 7.5 mg of oral methotrexate once weekly for 8 weeks. No topical agent except bland emollients was applied during the trial period. Psoriasis area severity index (PASI) was calculated as main outcome measure at entry level and follow up after one month and two months.
Results The mean percentage reduction of PASI was statistically significant (p=0.001) at both first and second follow up with oral colchicine. PASI-50 was achieved in 23.3% of respondent in colchicine group and 53.3% in methotrexate group (p<0.05).
Conclusion Oral colchicine is an effective therapy for chronic plaque psoriasis but it is less effective than methotrexate, the gold standard antipsoriatic therapy (p<0.05).
References
1. Griffiths CEM, Camp RDR, Barker JNWN. Psoriasis. In: Burns T, Breathnach S, Cox N, Griffiths C, eds. Rook’s Textbook of Dermatology, 7th edn. Massachusetts: Blackwell Publisher; 2004. P. 35.1-35.69.
2. Tan JK, Aphale A, Malaviya R et al. 2007, Mechanisms of action of etanercept in psoriasis. J Invest Dermatol 2007; 12: 38-45.
3. Naldi L, Griffiths CEM. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005; 52: 597-615.
4. Davis LS. New uses for old drugs. In: Wolverton SE, Wilkin JK, eds. Systemic Drugs For Skin Diseases. New York: WB Saunders; 1991. P. 364-6
5. Sullivan T, King L, Boyd A. Colchicine in dermatology. J Am Acad Dermatol 1998; 39: 993-9.
6. Cronstein BN, Molad Y, Reibman J et al. Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995; 96: 994-1002.
7. Bassak P, Chatterjee A. Oral colchicine in chronic plaque psoriasis. Indian J Dermatol Venereol Leprol 1993; 59: 168-171.
8. Wahba A, Cohen H. Therapeutic trials with oral colchicine in psoriasis. Acta Derm Venereol (Stockh) 1980; 60: 515-20.
9. Reich K, Mrowietz U. Treatment goals in psoriasis. J Der Deutschen Dermatologischen Gesellschaft 2007; 5:566-74.
10. Malkinson FD, Lynfield YL. Colchicine alopecia. J Invest Dermatol 1959; 33: 371-
84.
11. Kaidbey KH, Petrozzi, JW, Kligman AM. Topical colchicine therapy for recalcitrant psoriasis. Arch Dermatol 1975; 111: 33-6.
12. Johann EG, James TE. Psoriasis. In: Wolff K, Goldsmith LA, Katz SI et al., eds. Fitzpatrick’s Dermatology in General Medicine, 7th edn. San Francisco: McGraw-Hill,; 2007. 169-193.
Downloads
Published
Issue
Section
License
Copyright (c) 2016 Mohammed Saiful Islam Bhuiyan, Md. Akramullah Sikder, Muhammad Munir Rashid, Farzana Rabin
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
